Secondary interstitial lung disease specific to childhood associated with a connective tissue disease

Secondary interstitial lung disease (ILD) specific to childhood associated with a connective tissue disease (Orphanet code 264704) is a rare pulmonary condition in which the lung interstitium — the tissue and space surrounding the air sacs — becomes inflamed and damaged as a consequence of an underlying connective tissue disorder in pediatric patients. Connective tissue diseases that may give rise to this condition in children include juvenile dermatomyositis, systemic lupus erythematosus, juvenile idiopathic arthritis, systemic sclerosis, and mixed connective tissue disease. The lung involvement is considered secondary because it arises as a complication of the primary autoimmune or connective tissue process rather than as an isolated pulmonary disease. The condition primarily affects the respiratory system, leading to symptoms such as chronic cough, progressive shortness of breath (dyspnea), exercise intolerance, tachypnea (rapid breathing), and in some cases hypoxemia (low blood oxygen levels). Chest imaging, particularly high-resolution computed tomography (HRCT), may reveal ground-glass opacities, reticular patterns, or honeycombing depending on the stage and severity. Pulmonary function testing typically shows a restrictive pattern with reduced diffusion capacity. Because the disease occurs in childhood, it can significantly impact growth, development, and quality of life. Treatment is directed at controlling the underlying connective tissue disease and suppressing the autoimmune-mediated lung inflammation. Immunosuppressive therapies such as corticosteroids, methotrexate, mycophenolate mofetil, cyclophosphamide, and biologic agents may be employed depending on the specific connective tissue disease and severity of lung involvement. Supportive care including supplemental oxygen, pulmonary rehabilitation, and close monitoring of lung function is also important. Early recognition and multidisciplinary management involving pediatric pulmonologists and rheumatologists are essential to optimize outcomes, though the prognosis varies depending on the underlying connective tissue disease and the extent of pulmonary fibrosis.

Common questions about Secondary interstitial lung disease specific to childhood associated with a connective tissue disease